Searched for
FUNDRAISING IN PHARMACEUTICAL SECTOR
ETMarkets Smart Talk | Defence and electrification are multi-year structural themes for India: Prateek AgrawalGeopolitical shifts and the drive for self-reliance are creating long-term investment opportunities in India's defence and electrification ...- IPO calendar: Which new issues and listings will hit the market this week?The primary market anticipates a quiet week with no mainboard IPOs. Investor focus shifts to SME platforms, featuring one new IPO and sever...
- Why Motilal Oswal’s BFSI fund is betting big on capital market ecosystem: Prateek Agarwal of Motilal Oswal AMCPrateek Agarwal of Motilal Oswal AMC highlights a shift in financial sector growth from traditional banking to capital markets like AMCs, b...
- Manufacturing startup Scimplify in talks to raise $30-40 million from Hitachi Ventures, othersSpecialty chemical startup Scimplify is in talks to raise $30-40 million from Japanese investors led by Hitachi Ventures, valuing the compa...
- Torrent Pharma eyes Rs 12,500-crore bond sale next week. Check detailsNext week, Torrent Pharmaceuticals is set to launch a hefty debt sale, targeting around ₹12,500 crore in fundraising. This capital will pla...
- Fund X represents a 60% increase over previous $1.35 billion Fund IX closed in 2022In a landmark move, ChrysCapital has successfully garnered a staggering $2.2 billion for its latest venture, ChrysCapital X, marking a pivo...
- Pharma, healthcare firms eye Rs 13,000-cr IPO wave over 9 monthsIndian pharmaceutical and healthcare firms are set for a significant fundraising push, aiming to garner ₹12,000-13,000 crore through IPOs i...
- Pharma stocks in focus as Trump signals tariffs on imported medicinesPresident Trump announced potential tariffs on imported pharmaceuticals, impacting countries like India, a major supplier to the US drug ma...
- Trump signals major tariff on pharma imports, Indian drugmakers could face impactDonald Trump announced a forthcoming "major" tariff on pharmaceutical imports, aiming to incentivize drug companies to relocate operations ...
- India Inc gets past Rs 3 lakh crore mark in equity fundraceThose launching public issues this week include DAM Capital Advisors, Ventive Hospitality, Carraro India, Senores Pharmaceuticals, Transrai...
- India Inc leans on legal-tech firms to protect IPR as it expands to mature geographiesCompanies in the sectors including pharmaceutical, information technology, automobile and even conventional manufacturing companies are app...
- IPO activity to pick up pace in 2nd half of 2023: ReportThe IPO market in India has remained steady during Q1 of 2023, with four IPOs taking place during the quarter, one higher than in the same ...
- QIP fundraise in 2022 lowest in 6 years on strong balance sheets, reduced demandBankers said strong balance sheets in some sectors, sharp volatility in the stock market, high valuations, and consistent selling by foreig...
- Pharma businesses with strong quality compliance to emerge stronger as pandemic impact decreases: Ajay PiramalStressing that maintaining a strong focus on quality and compliance is another important area of growing significance in the pharma sector,...
- Pharma fever grips dealmakers despite M&A spike and a frenzy IPO yearMore than a dozen top bankers moved to strategic and M&A roles in pharmaceutical companies, spearheading mergers and acquisition as well as...
- Anthem Bio catches global buyout funds' eye, stake sale could see valuation rocket to $1 billionLaunched by ex-Biocon executive Ajay Bharadwaj, the Rs 1,200 crore Anthem Biosciences competes with Syngene International and GVK Bio. O3 C...
- Firm on pharma, Dilip Shanghvi surrenders NBFC licenceRBI puts on hold Shanghvi Finance's request for core investment company licence.
- Finance companies net 80% of the record Rs 74,000 crore raised via IPOs & OFSRetail services sector has netted about 3 per cent of the total IPO money raised so far in 2017.
- Look at FMCG, pharma for long term: Swati Kulkarni, UTI AMCPharma is an extremely company specific sector and one needs to be patient
- Kotak Private Equity may exit Rubicon with 3x returnsRubicon Research will also raise primary capital by selling another 20-25% through this round of fundraising that values the company at $20...
Load More
